Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2016 Jun 27.

Published in final edited form as: J Mol Biomark Diagn. 2016 May 20;1(Suppl 2):015. doi: 10.4172/2155-9929.S2-015

Table 2.

Association between the serum FGF21 levels and clinico-pathological parameters of ccRCC patients.

Parameter		FGF21	Χ² Test, p value
Parameter		High/Total (%)	Χ² Test, p value
Sex (n=98)	M	33/70 (47.1)	p=0.27
Sex (n=98)	W	16/28 (57.1)	p=0.27
Age (n=98)	<60	24/48 (50.0)	P=1.00
Age (n=98)	≥60	25/50 (50.0)	P=1.00
Obesity (n=95)	No	42/82 (51.2)	p=0.39
Obesity (n=95)	Yes	5/13 (38.5)	p=0.39
Risk Factors (n=92)	No	10/21 (47.6)	p=0.89
Risk Factors (n=92)	Ye s	35/71 (49.3)	p=0.89
TG (n=30)	High	2/3 (66.7)	p=0.9
TG (n=30)	Low	17/27 (63.0)	p=0.9
Stage (n=98)	I	19/37 (51.4)	p=0.68
	II	5/14 (35.7)
	III	10/20 (50.0)
	IV	15/27 (55.6)
Fuhrman Grade (n=94)	1	1/3 (3.3)	p=0.77
	2	11/25 (44.0)
	3	20/43 (46.5)
	4	13/23 (56.5)
Tumor Size (n=95)	1	23/45 (51.5)	p=0.57
	2	7/19 (36.8)
	3	13/25 (52.0)
	4	4/6 (66.7)
Metastasis (n=98)	No	35/73 (47.9)	p=0.49